Appendix 12Significant interaction effects for adenoidectomy with unilateral or bilateral grommets compared with non-surgical treatment
View in own window
| n (%) | Adenoidectomy with unilateral or bilateral grommets (n = 672)a | Non-surgical treatment (n = 343)b | RD (95% CI)c | NNTc | RR or mean difference (95% CI)c | Adjusted RR or mean difference (95% CI)c | p-value for interactionc |
|---|
| Primary outcome: failure after 12 months, n/N (%) |
|---|
| < 2 years | 462 (45.5) | 84/220 (38.2) | 27/242 (11.2) | −27.0% (−34.6% to −19.5%) | 4 | 0.29 (0.20 to 0.43) | 0.28 (0.13 to 0.56) | |
| ≥ 2 years | 553 (54.5) | 191/430 (44.4) | 109/123 (88.6) | −44.2% (−51.5% to −36.9%) | 3 | 0.50 (0.43 to 0.57) | 0.53 (0.44 to 0.65) | 0.09 |
| Secondary outcome: surgery during the first 12 months of follow-up, n/N (%) |
|---|
| Indication recurrent AOM | 486 (48.0) | 13/265 (4.9) | 53/221 (24.0) | −19.1% (−25.3% to −12.9%) | 6 | 0.21 (0.12 to 0.37) | 0.26 (0.11 to 0.61) | |
| Indication persistent OME | 526 (52.0) | 14/404 (3.5) | 43/122 (35.2) | −31.8% (−40.4% to −23.1%) | 4 | 0.10 (0.06 to 0.17) | 0.04 (0.01 to 0.18) | 0.03 |
| < 2 years | 462 (45.7) | 13/242 (5.4) | 53/220 (24.1) | −18.7% (−25.0% to −12.4%) | 6 | 0.22 (0.13 to 0.40) | 0.23 (0.09 to 0.57) | |
| ≥ 2 years | 550 (54.3) | 14/427 (3.3) | 43/123 (35.0) | −31.7% (−40.3% to −23.1%) | 4 | 0.09 (0.05 to 0.17) | 0.04 (0.01 to 0.18) | 0.02 |
| < 4 years | 578 (57.1) | 20/346 (5.8) | 56/232 (24.1) | −18.4% (−24.4% to −12.3%) | 6 | 0.24 (0.15 to 0.39) | 0.25 (0.11 to 0.57) | |
| ≥ 4 years | 434 (42.9) | 7/323 (2.2) | 40/111 (36.0) | −33.9% (−42.9% to −24.8%) | 3 | 0.06 (0.03 to 0.13) | 0.05 (0.01 to 0.18) | < 0.01 |
| Secondary outcome: presence of effusion for ≥ 50% of the time, n/N (%) |
|---|
| < 2 years | 179 (28.0) | 0/39 (0.0) | 0/140 (0.0) | – | – | – | – | |
| ≥ 2 years | 460 (72.0) | 153/374 (44.1) | 83/113 (73.5) | −29.4% (−39.0% to −19.7%) | 4 | 0.60 (0.51 to 0.71) | 0.45 (0.34 to 0.60) | 0.01 |
| Secondary outcome: time with effusion during the first 12 months of follow-up (weeks), mean (SD) |
|---|
| Indication recurrent AOM | 186 (29.1) | 0.4 (0.5) | 1.2 (3.0) | – | – | −0.9 (−1.8 to 0.0) | 0.1 (−0.1 to 0.2) | |
| Indication persistent OME | 453 (70.9) | 22.2 (15.6) | 36.8 (15.0) | – | – | −14.6 (−17.9 to −11.3) | −15.4 (−19.2 to −11.6) | < 0.01 |
| < 2 years | 179 (28.0) | 0.3 (0.3) | 1.3 (3.0) | – | – | −1.0 (−2.0 to −0.1) | 0.1 (−0.1 to 0.2) | |
| ≥ 2 years | 460 (72.0) | 21.9 (15.7) | 36.5 (15.3) | – | – | −14.6 (−17.9 to −11.3) | −15.4 (−19.2 to −11.6) | < 0.01 |
| < 4 years | 244 (38.2) | 8.6 (15.3) | 4.5 (12.4) | – | – | 4.1 (0.6 to 7.6) | −4.5 (−9.2 to 0.1) | |
| ≥ 4 years | 395 (61.8) | 23.2 (14.9) | 35.8 (14.9) | – | – | −12.7 (−16.0 to −9.3) | −14.4 (−18.3 to −10.5) | 0.01 |
- a
Black et al.,52 Casselbrant et al.,11 Dempster et al.,12 Hammarén-Malmi et al.,15 Kujala et al.,17 Mattila et al.,51 Maw and Bawden,10 Maw and Herod,19 MRC Multicentre Otitis Media Study Group20 and Nguyen et al.21
- b
MRC Multicentre Otitis Media Study Group,20 Koivunen et al.16 and Kujala et al.17
- c
Bold text indicates values are statistically significant.
